A prospective, randomized, double blind, single ascending dose study of SAR-425899 in healthy subjects

Trial Profile

A prospective, randomized, double blind, single ascending dose study of SAR-425899 in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs SAR 425899 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Acronyms SAD
  • Most Recent Events

    • 22 Sep 2016 New trial record
    • 16 Sep 2016 Results of population PK/PD model using data from SAD and MAD studies presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top